このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

糖尿病診断後の膵臓の健康の監視 (SAFE-D)

An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.

Participants will:

  • attend 3 study visits over 12 months time
  • provide a blood sample at each study visit
  • complete an anxiety questionnaire at each visit.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.

There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.

People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.

The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.

Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.

研究の種類

介入

入学 (推定)

5000

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:SAFE-D Trial Manager
  • 電話番号:+442381205154
  • メール:safed@soton.ac.uk

研究場所

      • Ashton-under-Lyne、イギリス、OL6 6HD
        • 積極的、募集していない
        • Ashton Medical Group
      • Birmingham、イギリス、B14 4DU
        • 募集
        • Yardley Wood Health Centre
        • コンタクト:
      • Bournemouth、イギリス、BH7 7DW
        • 積極的、募集していない
        • Bournemouth Research Hub
      • Bromborough、イギリス、CH62 6EE
        • 募集
        • Eastham Group Practice
        • コンタクト:
      • London、イギリス、NW10 2PT
        • 募集
        • Willesden Medical Centre
        • コンタクト:
      • London、イギリス、SW1P 2PF
        • 募集
        • South Westminster Centre
        • コンタクト:
      • London、イギリス、W7 1DR
        • 募集
        • The Cuckoo Lane Practice
        • コンタクト:
      • Manchester、イギリス、M14 6WP
        • 積極的、募集していない
        • Bodey Medical Centre
      • Manchester、イギリス、M23 1JX
        • 積極的、募集していない
        • Bowland Medical Practice
      • Manchester、イギリス、M23 2SY
        • 積極的、募集していない
        • The Maples Medical Centre
      • Nottingham、イギリス、NG17 4JL
        • 募集
        • King's Mill Hospital (Sherwood Forest) Research Van
        • コンタクト:
      • Portsmouth、イギリス、PO1 3HN
        • 積極的、募集していない
        • Portsmouth Research Hub
      • Rossendale、イギリス、BB4 5SL
        • 募集
        • Hazelvalley Family Practice
        • コンタクト:
      • Ruislip、イギリス、HA4 8NX
        • 募集
        • Pembroke Centre (Hillingdon)
        • コンタクト:
      • Southampton、イギリス、SO30 3JB
        • 募集
        • Moorgreen Hospital
        • コンタクト:
      • Southampton、イギリス、SO15 33UA
        • 積極的、募集していない
        • Southampton Research Hub (Shirley Research Hub)
      • Uttoxeter、イギリス、ST14 8JG
        • 募集
        • Balance Street Health Centre
        • コンタクト:
      • Uxbridge、イギリス、UB8 1UW
        • 募集
        • Civic Centre
        • コンタクト:
      • Walsall、イギリス、WS6 6EW
        • 募集
        • Quinton Practice
        • コンタクト:
      • Weymouth、イギリス、DT4 0QE
        • 積極的、募集していない
        • Weymouth Research Hub
    • Cheshire
      • Sandbach、Cheshire、イギリス、CW11 1EQ
        • 積極的、募集していない
        • Ashfields Primary Care Centre
    • Kent
      • Maidstone、Kent、イギリス、ME16 9QQ
        • 募集
        • Maidstone and Tunbridge Wells NHS Trust
        • コンタクト:
    • Leicester Forest East
      • Leicester、Leicester Forest East、イギリス、LE3 3LW
        • 募集
        • Forest Medical Group
        • コンタクト:
    • Leicestershire
      • Kibworth Beauchamp、Leicestershire、イギリス、LE8 0LG
        • 募集
        • South Leicestershire Medical Group
        • コンタクト:
    • Staffordshire
      • Burton-on-Trent、Staffordshire、イギリス、DE14 3RH
        • 募集
        • Peel Croft Surgery
        • コンタクト:
      • Kingswinford、Staffordshire、イギリス、DY6 8DN
        • 募集
        • Kingswinford Medical Practice
        • コンタクト:
      • Leek、Staffordshire、イギリス、ST13 6QR
        • 募集
        • Park Medical Centre
        • コンタクト:
      • Stratford-upon-Avon、Staffordshire、イギリス、CV37 6HJ
        • 募集
        • Trinity Court Surgery
        • コンタクト:
    • Surrey
      • Brockham、Surrey、イギリス、RH3 7NJ
        • 募集
        • Brockwood Medical Practice
        • コンタクト:
      • Epsom、Surrey、イギリス、KT17 4BL
        • 募集
        • Integrated Care Partnership/ The Old Cottage Hospital
        • コンタクト:
      • Warlingham、Surrey、イギリス、CR6 9NW
        • 募集
        • Warlingham Green Medical Practice
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年~84年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
  • Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
  • Willing to provide up to 30 mL of blood for each study visit
  • Willing and eligible to undergo MRI or CT scan
  • Understands the study process and is willing to take part in the study and sign the informed consent form

Exclusion Criteria:

  • Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
  • A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
  • Under investigation for or confirmed pancreatic cancer
  • Under investigation/surveillance for pancreatic cyst
  • Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
  • Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
  • BMI > 40 at the time of consent
  • Blood transfusion within 1 month
  • Solid organ transplant recipient
  • Currently pregnant
  • Needing dialysis

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Interventional

Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team.

Avantect test

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Sensitivity of the Avantect test
時間枠:The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.

The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed.

The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
Specificity of the Avantect test
時間枠:The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis.

The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

二次結果の測定

結果測定
メジャーの説明
時間枠
Stage shift
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data.

Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
時間枠:The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05.

The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Resection rate of pancreatic cancer
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Resectability
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

Percentage of pancreatic cancers deemed resectable by the study MDST.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

その他の成果指標

結果測定
メジャーの説明
時間枠
Time-to-event outcomes
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Overall survival
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To estimate the overall survival of study participants.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
Effect of the Avantect test on state anxiety over time
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To assess the effect of the Avantect test on state anxiety over time.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
High-grade neoplasia
時間枠:The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

To investigate the performance characteristics for high-grade neoplasia.

The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月21日

一次修了 (推定)

2029年7月29日

研究の完了 (推定)

2032年7月1日

試験登録日

最初に提出

2025年1月27日

QC基準を満たした最初の提出物

2025年1月27日

最初の投稿 (実際)

2025年1月31日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年3月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • RHMGSU0292

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。